Search the Newsreel

Kaplan Fox is Investigating Cellebrite DI Ltd. (NASDAQ: CLBT) for Potential Securities Law Violations

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Cellebrite DI Ltd. (NASDAQ: CLBT). This investigation follows Cellebrite's second-quarter results, which missed ARR projections, a reduction in full-year guidance, and an abrupt CEO change, leading to a significant 29% drop in …

Cellebrite DI Ltd (CLBT) Stock Up 3.1% and Still Undervalued -- GF Score: 84/100

Cellebrite DI Ltd (CLBT) shares rose 3.1% to $11.14 but are still considered undervalued with a GF Value estimate of $16.09, suggesting a 30.8% margin of safety. The stock boasts a strong GF Score of 84/100 due to robust fundamentals and growth potential, despite …

CLBT|Cellebrite DI Ltd|Price:11.110|Chg%:+0.310

Cellebrite DI (NASDAQ:CLBT) Given New $16.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has lowered its price target for Cellebrite DI (NASDAQ:CLBT) from $20.00 to $16.00, while maintaining an "overweight" rating. This new target implies a potential upside of 45.79% from the stock's current price of $10.97. Other analysts have also adjusted their …

Cellebrite DI (NASDAQ:CLBT) Sees Unusually-High Trading Volume After Strong Earnings

CLBT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Cellebrite DI Ltd.

SueWallSt has initiated an investigation into potential securities law violations by Cellebrite DI Ltd. (NASDAQ: CLBT) following a significant drop in its share price. The investigation stems from Cellebrite's Q2 2026 revenue falling below analyst expectations and the company subsequently lowering its full-year 2026 …

Cellebrite DI (CLBT) Cuts Guidance And Changes CEO, Is The Stock Now Cheap?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Cellebrite DI (CLBT) has come under fresh scrutiny after its August 13 Q2 2026 earnings report, guidance cut, and CEO transition, with Levi …

Needham cuts Cellebrite stock price target on guidance reduction

Needham has lowered its price target for Cellebrite DI Ltd. (NASDAQ:CLBT) to $12.50 from $15.00, while maintaining a Buy rating. This adjustment follows Cellebrite's reduced fiscal 2026 guidance for annual recurring revenue and total revenue, alongside the appointment of Shiven Ramji as the new …

Does Cellebrite DI’s Lowered 2026 Outlook and New CEO Reset Its AI Narrative (CLBT)?

In August 2026, Cellebrite DI Ltd. reported second-quarter results showing revenue of US$131.14 million and net income of US$6.37 million, while lowering its full-year 2026 revenue guidance to US$555 million–US$561 million and announcing Shiven Ramji's appointment as CEO, succeeding Thomas E. Hogan. The combination …

ETFs Investing in Cellebrite DI Ltd. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Cellebrite DI Ltd. (CLBT), providing detailed information such as market value, weight, issuer, management style, expense ratio, AUM, price change, relative volume, and 3-year NAV total return for each fund. It aims …

Cellebrite DI (CLBT) Names Shiven Ramji As Next CEO

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Cellebrite DI (NasdaqGS: CLBT) announced a planned CEO transition, with Shiven Ramji set to succeed Thomas E. Hogan. Ramji joined Cellebrite DI earlier this year as President, …

Cellebrite (CLBT) CEO gets 339,484-share award and withholds 139,713 shares for taxes

Cellebrite DI Ltd. CEO Thomas E. Hogan received an award of 339,484 ordinary shares on August 11, 2026, after performance conditions from awards granted in September 2025 were met. Subsequently, 139,713 shares were withheld and sold on August 12, 2026, at a weighted average …

Cellebrite DI Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Cellebrite DI (CLBT)

Levi & Korsinsky, LLP has announced an investigation into Cellebrite DI Ltd. (CLBT) following a significant stock drop of over 30% after the company's Q2 2026 results. The investigation focuses on whether Cellebrite made misleading statements regarding its 2026 annual recurring revenue (ARR) and …

Cellebrite DI (CLBT) Names Shiven Ramji CEO As Revenue Guidance Is Cut

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Cellebrite DI (NasdaqGS: CLBT) announced a planned CEO transition, with Shiven Ramji set to succeed Thomas E. Hogan. Ramji joined Cellebrite DI earlier this year as President, …

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Platform Evolution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Cellebrite DI (NASDAQ:CLBT) CEO Thomas Hogan Sells 139,713 Shares of Stock

Cellebrite DI (NASDAQ:CLBT) CEO Thomas Hogan sold 139,713 shares of the company's stock for approximately $2.15 million, reducing his direct ownership by 15.02%. The sale comes as Cellebrite's stock fell, trading below its moving averages, and the company recently lowered its 2026 revenue and …

Cellebrite DI Ltd (CLBT) (Q2 2026) Earnings Call Highlights: ARR Misses Guidance, Full-Year ...

This article first appeared on GuruFocus. ARR: Increased 21% to $508 million, missing the bottom end of guidance. Revenue: $131 million, up 16% year-over-year. Subscription Revenue: $119.5 million, up 16%, representing 91% of total revenue. Gross Profit: Increased 16% to $112 million, with a …

Stock Market Today, Aug. 13: Cellebrite Shares Plummet 29% After Missing Earnings, Cutting 2026 Revenue Guidance

Cellebrite (CLBT) boosts H1 2026 revenue 17% while net income falls sharply

Cellebrite Q2: This 33% Selloff Looks Like An Overreaction (NASDAQ:CLBT)

Cellebrite DI Ltd. (CLBT) experienced a significant 33% stock drop post-earnings, which the author believes is an overreaction. Despite missing Q2 guidance for ARR and revenue growth, and facing management transition and slower Inseyets conversions, the company maintains strong core products, high retention, and …

Cellebrite DI Releases Q2 2026 Financial Results

Cellebrite DI Ltd. reported mixed Q2 2026 financial results, with earnings per share meeting expectations at $0.11, while revenue of $131.1M slightly missed the $131.9M estimate. Despite the revenue miss, the company showed strong year-over-year growth, with total revenue up 16.0% and subscription services …

Cellebrite DI Ltd. Stock Analysis: 5-Day Bearish Momentum Insights

Cellebrite DI Ltd. (CLBT) stock has crashed to $10.22 following a post-earnings decline, placing it deep in oversold territory according to its RSI readings across multiple timeframes. The company missed annual recurring revenue expectations due to delayed transactions and slower customer migration gains, leading …

Cellebrite DI (NASDAQ:CLBT) Sets New 52-Week Low - Time to Sell?

Cellebrite DI (NASDAQ:CLBT) shares recently fell to a new 52-week low of $10.55, despite previously closing at $15.25. While insider selling totaling $2.48 million occurred over the last three months, analysts maintain a "Moderate Buy" consensus with an average price target of $21.80. Institutional …

Cellebrite DI Q2 Earnings Call Highlights

Cellebrite Appoints Shiven Ramji CEO as Company Sharpens Product Strategy

Cellebrite DI Ltd. has appointed Shiven Ramji as its new CEO, succeeding Thomas E. Hogan, to sharpen its product strategy with a focus on AI and new growth opportunities. Ramji, previously president of products and technology, will lead the company's expansion beyond digital forensics …

Cellebrite DI Ltd. (CLBT) Q2 Earnings and Revenues Miss Estimates

Cellebrite DI Ltd. (CLBT) reported Q2 earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.12, and revenues of $131.14 million, which also fell short of expectations. The company's shares have declined by 15.4% year-to-date, contrasting with the S&P 500's gain, and …

Cellebrite (CLBT) CRO sells 411 shares to cover RSU tax obligations

Cellebrite DI Ltd.'s Global Chief Revenue Officer, Jewell Marcus, sold 411 ordinary shares on August 12, 2026, at a weighted average price of $16.0678 per share. This transaction was executed to cover tax obligations related to the vesting of Restricted Stock Units (RSUs) granted …

CELLEBRITE DI ($CLBT) Releases Q2 2026 Earnings

This article first appeared on GuruFocus. ARR: Increased 21% to $508 million, missing the bottom end of guidance. Revenue: $131 million, up 16% year-over-year. Subscription Revenue: $119.5 million, up 16%, representing 91% of total revenue. Gross Profit: Increased 16% to $112 million, with a …

Cellebrite Appoints Shiven Ramji Chief Executive Officer, Succeeding Thomas E. Hogan

Cellebrite DI Ltd. announced that Shiven Ramji has been appointed Chief Executive Officer, succeeding Thomas E. Hogan, as part of a planned transition. The company also reported its second-quarter 2026 financial results, with total Annual Recurring Revenue (ARR) of $507.8 million, up 21% year-over-year, …

Cellebrite DI Ltd. (CLBT) Tops Q2 EPS by 4c ; Offers Guidance

Cellebrite DI Ltd. (CLBT) reported Q2 EPS of $0.11, exceeding analyst estimates by $0.04, with revenue of $131.14 million. The company provided Q3 2026 revenue guidance of $145-148 million and full-year 2026 revenue guidance of $550-560 million, both slightly below consensus estimates.

3 AI And Data Analytics Stocks Worth Watching Right Now

This article highlights three AI and data analytics stocks—Cellebrite DI (CLBT), Tenable Holdings (TENB), and Similarweb (SMWB)—that are worth watching due to their strategic positions in emerging technology areas. It details their operations, market caps, and why they stand out, such as Cellebrite's role …

Cellebrite Di Ltd. (CLBT) executive Thomas E. Hogan plans large share sale

Cellebrite Di Ltd. executive Thomas E. Hogan has filed a Form 144 notice indicating his intent to sell 339,484 ordinary shares through Morgan Stanley Smith Barney LLC on or around August 12, 2026. These shares were acquired on August 11, 2026, as Performance Shares …

Cellebrite DI (CLBT) Shares Climbed, What Is Driving Attention Now?

Cellebrite DI (CLBT) is gaining investor attention ahead of its Q2 2026 earnings report and following an expanded partnership with SkySafe for drone detection. The company's stock has seen a 25.67% return over 90 days, despite a year-to-date dip, with its recurring revenue model …